Health-related quality of life was better maintained with pembrolizumab than with ipilimumab in patients with ipilimumab-naive advanced melanom, according to findings of this study.
Rare variants in low- or intermediate-risk CMM genes may influence familial CMM predisposition, according to the authors of this study.
As facial areas that are prone to skin cancer are disproportionately missed during sunscreen application, other mechanisms of sun protection should be widely promoted such as UV blocking sunglasses, according to authors of this study.
Skin colour may be an important modifier of melanoma risk, according to study authors. Incorporating skin colour and other non-genetic factors into genetic studies therefore may allow for an improved understanding of melanoma susceptibility, according to study authors.
The results of the Scottish and pooled analyses suggest that those receiving an initial excision for melanoma in primary care do not have poorer survival or increased morbidity compared to those being initially treated in secondary care.
The introduction of immune checkpoint-blocking agents has resulted in a significant survival benefit in metastatic melanoma patients, according to authors of this study.
Study authors advise that as melanomas are most likely to arise in the absence of a pre-existing naevus, particularly nodular melanomas, public health campaigns should emphasise the detection of suspicious de novo lesions, as well as of changing lesions.
The results of this study allow tailoring of preventive advice to melanoma patients to reduce their risk of future primary and recurrent disease, according to the authors.
This review outlines all published biomarkers for immune checkpoint inhibitors therapy for melanoma patients and highlights potential candidate markers for future research.
Sociodemographic and psychological characteristics should be considered when including patients at elevated risk of melanoma in a targeted surveillance programme, according to authors of this study.